2013
Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report
Nardone B, Saddleton E, Laumann AE, Edwards BJ, Raisch DW, McKoy JM, Belknap SM, Bull C, Haryani A, Cowper SE, Abu-Alfa AK, Miller FH, Godinez-Puig V, Dharnidharka VR, West DP. Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report. Pediatric Radiology 2013, 44: 173-180. PMID: 24057195, PMCID: PMC3946726, DOI: 10.1007/s00247-013-2795-x.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisSystemic fibrosisGadolinium-based contrast agentsDrug Administration Adverse Event Reporting SystemAdverse Event Reporting SystemEvent Reporting SystemRenal functionPediatric casesResearch RegistryContrast agentsFibrosisDuplicate reportingU.S. FoodSystematic searchReported numberRegistryChildrenReporting systemFAERSExposureReportAgentsMethodsWeCases
2012
Linking Drugs to Obscure Illnesses: Lessons from Pure Red Cell Aplasia, Nephrogenic Systemic Fibrosis, and Reye’s Syndrome. A Report From the Southern Network on Adverse Reactions (SONAR)
Bennett CL, Starko KM, Thomsen HS, Cowper S, Sartor O, Macdougall IC, Qureshi ZP, Bookstaver PB, Miller AD, Norris LB, Xirasagar S, Trenery A, Lopez I, Kahn A, Murday A, Luminari S, Cournoyer D, Locatelli F, Ray P, Mattison DR. Linking Drugs to Obscure Illnesses: Lessons from Pure Red Cell Aplasia, Nephrogenic Systemic Fibrosis, and Reye’s Syndrome. A Report From the Southern Network on Adverse Reactions (SONAR). Journal Of General Internal Medicine 2012, 27: 1697-1703. PMID: 22692632, PMCID: PMC3509314, DOI: 10.1007/s11606-012-2098-1.ChaptersConceptsPure red cell aplasiaNephrogenic systemic fibrosisChronic kidney disease patientsSerious adverse drug reactionsKidney disease patientsRed cell aplasiaReye's syndromeNSF casesCell aplasiaDisease patientsSystemic fibrosisAdministration of aspirinDanish Medicines AgencyAdverse drug reactionsYears of identificationCKD patientsCounter medicationsDrug reactionsAdverse reactionsGadodiamide administrationObscure illnessPediatric useMedicines AgencyPatientsSyndrome
2008
Gadolinium – is it to blame?
Cowper SE. Gadolinium – is it to blame? Journal Of Cutaneous Pathology 2008, 35: 520-522. PMID: 18399814, DOI: 10.1111/j.1600-0560.2008.01027.x.Commentaries, Editorials and Letters
2007
Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis
High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. Journal Of The American Academy Of Dermatology 2007, 56: 710-712. PMID: 17289213, DOI: 10.1016/j.jaad.2007.01.022.Peer-Reviewed Original ResearchGadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis1
Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis1. Radiology 2007, 242: 647-9. PMID: 17213364, DOI: 10.1148/radiol.2423061640.Commentaries, Editorials and Letters
2003
Nephrogenic fibrosing dermopathy: the first 6 years
Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Current Opinion In Rheumatology 2003, 15: 785-790. PMID: 14569211, DOI: 10.1097/00002281-200311000-00017.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNephrogenic fibrosing dermopathyRecent case reportsCase reportCutaneous fibrosing disorderYellow scleral plaquesDistinct clinical patternsDual immunohistochemical stainingAntiphospholipid antibodiesRenal insufficiencyClinical patternDual immunolabelingFibrosing disorderSystemic disordersClinical spectrumScleral plaquesDisease onsetEpidemiologic dataSpindle cellsImmunohistochemical stainingDisease triggersSkin conditionsDisease pathogenesisNormal skinRegistry projectDiagnostic tests